Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced.

Read ahead to know now why the heart beats rapidly all of a sudden for a few seconds what triggers it and when to consult a ...

Tri-City Cardiology, a Phoenix-based cardiology group among the largest and most respected in the country, has expanded its ...

MIT-alumni-founded Thermedical advances novel deep-tissue ablation technology to address critical unmet needs in severe ventricular tachycardia ...

Milestone Pharmaceuticals Inc.’s CARDAMYST nasal spray wins FDA approval for PSVT, but faces tough competition and market risks. Click for this MIST stock update.

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

With the paid subscription, you also get additional benefits such as cloud storage, blood pressure monitoring, medication ...

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...

Investing.com -- Milestone Pharmaceuticals (NASDAQ:MIST) stock surged 35% after the company received FDA approval for CARDAMYST, the first self-administered nasal spray for adults with paroxysmal ...

As of Tuesday, December 16, Milestone Pharmaceuticals Inc.’s MIST share price has surged by 8.53%, which has investors ...

Atrial fibrillation (AF) is a cardiac arrhythmia most prevalent in older age groups and with underlying structural heart disease. However, it can occasionally present in younger, otherwise healthy ...